Linda DiMeglio, MD, MPH | Indiana University and Riley Hospital for Children | Indianapolis, IN
Stanford University | Stanford, CA
University of California, San Francisco | San Francisco, CA
Barbara Davis Center for Childhood Diabetes, University of Colorado | Aurora, CO
Yale University | New Haven, CT
University of Iowa Health Care | Iowa City, IA
Indiana University, Riley Hospital for Children | Indianapolis, IN
Children's Mercy Hospital | Kansas City, MO
Sanford Research | Sioux Falls, SD
Benaroya Research Institute | Seattle, WA
Joslin Diabetes Center | Boston, MA
University of Minnesota | Minneapolis, MN
ITN066AI
Active
The goal of the Immune Tolerance Network’s (ITN) type 1 diabetes clinical trials is to find new therapies that can help people maintain some natural insulin production, even after stopping treatment. Two previous ITN trials,T1DAL and AbATE, showed that this was possible in some participants. We now want to know how long these effects can last.
The T1DES study (T1D Extension Study) will follow graduates from T1DAL, AbATE, and EXTEND to determine how long they continue to produce insulin. T1DES will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
This study is observational, meaning there are no study medications or experimental procedures.
Depending on your level of insulin production, T1DES participation may be as short as one return visit or could be up to five years. Participation requires 2 visits per year. These visits will include:
*MMTTs tell doctors how much insulin the body is still making. It involves drinking a special drink that contains a mixture of protein, fat, and carbohydrates. Blood samples are taken at specific time points after drinking.
To learn more about this study and whether you are eligible to participate, please visit the study website: T1DES.org.
